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ABSTRACT
Objectives: To evaluate the accuracy of routine data for
costing inpatient resource use in a large clinical trial and
to investigate costing methodologies.
Design: Final-year inpatient cost profiles were derived
using (1) data extracted from medical records mapped to
the National Health Service (NHS) reference costs via
service codes and (2) Hospital Episode Statistics (HES)
data using NHS reference costs. Trust finance
departments were consulted to obtain costs for
comparison purposes.
Setting: 7 UK secondary care centres.
Population: A subsample of 292 men identified as
having died at least a year after being diagnosed with
prostate cancer in Cluster randomised triAl of PSA testing
for Prostate cancer (CAP), a long-running trial to evaluate
the effectiveness and cost-effectiveness of prostate-
specific antigen (PSA) testing.
Results: Both inpatient cost profiles showed a rise in
costs in the months leading up to death, and were broadly
similar. The difference in mean inpatient costs was £899,
with HES data yielding ∼8% lower costs than medical
record data (differences compatible with chance, p=0.3).
Events were missing from both data sets. 11 men (3.8%)
had events identified in HES that were all missing from
medical record review, while 7 men (2.4%) had events
identified in medical record review that were all missing
from HES. The response from finance departments to
requests for cost data was poor: only 3 of 7 departments
returned adequate data sets within 6 months.
Conclusions: Using HES routine data coupled with NHS
reference costs resulted in mean annual inpatient costs
that were very similar to those derived via medical record
review; therefore, routinely available data can be used as
the primary method of costing resource use in large
clinical trials. Neither HES nor medical record review
represent gold standards of data collection. Requesting
cost data from finance departments is impractical for large
clinical trials.
Trial registration number: ISRCTN92187251;
Pre-results.
INTRODUCTION
While guidelines have long recommended
reporting resource use and unit costs separ-
ately,1 2 there is little advice about appropri-
ate costing methodology. There is
consistency in the basic principles of costing,
but guidelines contain disagreements about
how best to apply costs to resource use.3
There has been substantial variation in
costing methods applied within cost-
effectiveness analyses (CEA) and results may
be affected by the costing methods used.4
Attempts to improve the standardisation of
costing methods to ensure comparability
across studies5–7 have been hampered by a
Strengths and limitations of this study
▪ Resource-use data collection from medical
records was both meticulous and comprehen-
sive, allowing us to assess the suitability of the
Hospital Episode Statistics (HES) inpatient data
set for costing purposes in an economic evalu-
ation alongside a clinical trial.
▪ The final year of life was accurately identified by
analysing data retrospectively.
▪ The study focuses on a single clinical area only.
▪ Problems with using HES data include its limited
geographical coverage, lack of sensitivity to
details of procedures, uncertain definition of a day
case and administrative changes in past years.
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lack of transparency in reporting, with many studies
reporting costing methodologies in an opaque fashion.8
There are necessary trade-offs between research
resources available and the accuracy of the costs that can
be obtained. Typically, health economists have collected
information on resources consumed by extracting data
from medical records or by asking patients themselves to
supply data. Similarly, cost data relating to resource use
identiﬁed within a trial is commonly obtained by asking
ﬁnance departments in the National Health Service
(NHS) trusts to supply data; over half the Health
Technology Assessment (HTA) studies that reported an
economic evaluation used costs from local sources.9
However, these can be time consuming and costly pro-
cesses, and may not represent the best use of research
resources. Increased access to routinely collected data in
the UK, such as the NHS reference costs and the
Hospital Episode Statistics (HES) data set in
England,10 11 is affording researchers opportunities for
obtaining costs in healthcare more readily. For example,
HES data can be used to identify relevant resource use,
while the NHS reference costs can potentially be used in
place of data from ﬁnance departments. Each hospital
inpatient stay recorded in HES is assigned a healthcare
resource group (HRG) code, with HRGs representing
collections of procedures that typically use similar levels
of resources (based on the diagnosis-related groups
(DRGs) used in the USA). However, data such as HES
are primarily recorded for the purposes of administering
the health service and, as such, are not speciﬁcally
designed for research purposes; therefore, there may be
limitations to the usefulness of the data. In addition, the
data have not been validated for use in economic evalu-
ation costing studies, and therefore it is not possible to
say how accurate or complete they are; researchers and
policymakers cannot be conﬁdent the results reported
are correct without some form of validation having been
undertaken.12
Healthcare at the end of life is a topic of current
national interest, with the National Institute for Health
and Care Excellence (NICE) having issued additional
guidance for considering interventions that might
increase the length of life for patients close to death.13
A sharp increase in the costs associated with healthcare
resources consumed is typically observed in the last
months before death,14–16 with men dying from prostate
cancer incurring their highest costs close to diagnosis
and death.17
In this study, the aim was to compare three methods
of costing end-of-life care for a sample of men in the
Cluster randomised triAl of PSA testing for Prostate
cancer (CAP)). The ﬁrst method was based on
resource-use data collected through medical record
review, with costs applied via national reference costs.
The second method utilised routinely collected HES
data, with national reference costs applied. A third com-
parative set of information on cost data was sought from
ﬁnance departments. The analysis was restricted to the
inpatient component of the total costs, as this is known
to be a key healthcare cost driver.18
METHODS
Selection of patients and events
The CAP Trial (ISRCTN92187251) is evaluating the
effectiveness and cost-effectiveness of prostate-speciﬁc
antigen (PSA) testing with a primary outcome of pros-
tate cancer mortality. General practices in eight centres
within the UK (Bristol, Cardiff, Cambridge, Leeds,
Newcastle, Birmingham, Shefﬁeld and Leicester) were
allocated to either population-based PSA testing as part
of the ProtecT trial or usual practice (the provision of
an informed choice to men seeking advice about the
test).19 Participants were all men aged 50–69 years who
were registered with one of the study practices. As part
of the CAP Trial, a detailed review of medical records
was conducted for men who were diagnosed with pros-
tate cancer or died with prostate cancer or bone metas-
tases according to the death certiﬁcate.19
Inpatient resource-use data for a convenience sub-
sample of men from the CAP Trial were made available
in order to carry out this methodological study. The
sample included men in CAP who (1) had a diagnosis
of prostate cancer notiﬁed by the Health and Social
Care Information Centre (HSCIC) and conﬁrmed in
medical records, (2) died of prostate cancer or other
causes at least a year after ﬁrst being investigated for
prostate cancer and (3) had undergone the complete
medical record review process. As such, they represent a
homogeneous, but arbitrary rather than truly random,
sample that excludes men who died rapidly following
diagnosis. Men from each of the seven CAP centres in
England (Bristol, Birmingham, Cambridge, Newcastle,
Shefﬁeld, Leeds and Leicester) were included and were
drawn from intervention and usual care arms of the
trial, with the researcher ( JCT) blinded to trial arm.
Descriptive statistics including age, index of multiple
deprivation (IMD, an area-level measure of depriv-
ation20) and cause of death were obtained.
Measurement of resource use
Inpatient resource use was identiﬁed using two different
sources. All inpatient events whether related to prostate
cancer or not were identiﬁed by a detailed review of
medical records conducted by trained research assis-
tants. Start and end dates for each event were recorded
along with the type of ward in which the event took
place. HES inpatient records, including episode start
dates, durations and HRG V.3.5 codes,21 were also avail-
able. Day cases were excluded from the analysis
because there is ambiguity over their deﬁnition.22 In
the absence of HES data describing the type of stay,
HES day cases were deﬁned as stays of zero nights.
Hospice care was also excluded from the analysis
because it is often provided outside the NHS and is not
recorded in HES.
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Application of costs
For resource use identiﬁed in medical record review,
costs were assigned on the basis of the type of ward in
which the inpatient event had occurred and the length
of stay. Costs were applied using the publicly available
NHS reference costs, which include both direct and
indirect costs.23 Ward types for each event were mapped
to service codes describing the specialty under which
the man was treated in the NHS reference costs. For
example, urology has a service code of 101, while cardi-
ology is represented by 320. For each of the listed
service codes, median costs for a patient’s overnight stay
were derived from a data set containing organisation-
speciﬁc costs for 2010/2011.24 Elective and non-elective
inpatient (both short and long) stays were included in
the averages because information on whether the stay
was elective or not was not available for inpatient events
in the medical record review data set; primary care trust
data and outsourced events were excluded as we were
interested in NHS secondary care costs. Where the ward
type was unknown or unclear in the medical records,
mapping to service codes was not possible. Mean imput-
ation was used in these cases: a mean cost per night
(weighted by the number of nights) was derived from
all episodes with available cost data, and applied to
events with missing costs. Sensitivity to the imputed
value was explored by using the maximum and
minimum costs.
For resource use identiﬁed via HES records, HRG
V.3.5 codes were used to apply costs directly from the
2005/2006 NHS reference costs (the most recent year
for which HRG V.3.5 costs were published) on the basis
of individual episodes. Elective and non-elective admis-
sions were taken into account. A per diem costing was
applied to excess bed days beyond the standard
number of days anticipated for a given HRG (known as
the ‘trim point’25). Costs were inﬂated to 2010/2011
levels using the hospital and community health services
index.26
A third comparison was made by requesting cost data
from trust ﬁnance departments for a small number of
men whose medical record review was completed earli-
est. Trusts in each of the eight areas participating in
CAP were sent a tailored questionnaire designed to min-
imise the burden on respondents by only requesting
information relating to events that occurred within that
trust. For example, trusts were only asked to supply the
cost of a patient’s overnight stay in a cardiology ward if a
man in that trust had used the resource; this approach
resulted in questionnaires of varying length.
Questionnaires were emailed to named contacts identi-
ﬁed by CAP researchers from information about the
ﬁnance departments on each trust’s website, with a
request to return the information within 4 weeks.
Periodic reminders were sent by email over a period of
5 months, and departments were contacted by tele-
phone in order to ascertain whether there might be any
problems with fulﬁlling the request.
Analysis
Statistical analysis was carried out using Stata V.12
(StataCorp. Stata Statistical Software: Release 12. College
Station, TX: StataCorp LP, 2011). For medical record
review resource use, NHS reference costs were assigned
to the month prior to death in which they occurred on
a per diem basis; for long stays, therefore, costs could fall
in more than 1 month. For HES-identiﬁed resources,
costs were assigned to the month in which the ﬁrst day
of the episode occurred to reﬂect the ﬁxed-cost nature
of HRGs. Inpatient cost proﬁles were derived for
mean costs incurred on a monthly basis over the last
year of life.
Total mean resource-use costs over the ﬁnal year of
life were also calculated for the two methods of collect-
ing resource-use data costed using NHS reference costs,
and differences were derived for each month prior to
death. Two-sample paired t tests were used to derive p
values for the differences between costs; a 1% signiﬁ-
cance level is appropriate for the multiple tests carried
out on these data. A manual inspection of inpatient
events occurring in medical record review and HES
records was conducted, with the aim of identifying
missing events in either data set.
RESULTS
Data sets
HES and medical record review data were available for
292 men, representing seven centres participating in
CAP in England. The men died between 2004 and 2012
at ages 52–78 years (mean (SD) age at death: 68.2
(5.4)). They had been diagnosed with prostate cancer at
a mean (SD) age of 65.6 (5.3) years, and lived for a
mean of 2 years and 8 months from diagnosis until
death (SD=18 months). Two hundred and sixty-two of
the men had undergone assessment by a committee set
up to determine cause of death from data collected
during medical record review;19 of these, 161 men
(61.5%) were assessed as having died of prostate cancer.
Of the remaining men, 64 (24.4%) had another cancer,
13 (5.0%) had cardiovascular disease and 24 (9.2%) had
other causes cited on the death certiﬁcate. The men
had a mean (SD) IMD score of 25.0 (17.3). Costs were
imputed for 362/7722 (4.7%) of nights in the medical
record review data set.
Comparative costs were requested from trust ﬁnance
departments for a subset of 88 of these men, via ques-
tionnaires varying in length between three and seven
pages. Full sets of requested costs were received from
three out of the seven ﬁnance departments that were
contacted, with response times ranging from 9 to
106 days; the shortest questionnaire resulted in the
fastest response. A further partial set was received from a
fourth department after a period of 125 days. Three
departments had been unable or unwilling to supply
costs after a period of 6 months. One department
returned an extract from the NHS reference costs, and
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the remaining three varied in terms of the factors
included in the costs. Owing to the poor response rate
and inconsistencies in reporting, the strategy was not
considered successful and no further data were
requested.
End-of-life inpatient cost profiles
Month-by-month inpatient cost proﬁles over the ﬁnal
year of life were derived using resource-use data from
HES and medical record review costed with NHS refer-
ence costs (ﬁgure 1). The proﬁles were similar to one
another and follow the expected pattern of a substantial
rise in costs in the ﬁnal months leading up to death.
The 95% CIs overlapped at each month, and there was
no discernible pattern that might suggest the existence
of a systematic error between the two costing methods.
The inpatient cost proﬁles diverged slightly as death
approached, but the values were not signiﬁcantly differ-
ent at the 1% signiﬁcance level. The wider variation in
month 11 prior to death arose from a single man with a
very lengthy stay beyond the trim point in the HES data
set. Insufﬁcient data returned from ﬁnance departments
precluded the derivation of an inpatient cost proﬁle
using this costing methodology.
Mean resource use per patient
The mean resource use per man over the ﬁnal year of
life was £11 122 (95% CI £9083 to £13 161) using
medical record review and national reference costs, and
£10 223 (95% CI £8880 to £11 565) using HES data with
reference costs. Costs associated with HES data were
slightly lower (about 8%) than those associated with
medical record review data, but the difference was com-
patible with chance (p=0.3). Sensitivity analysis indicated
that this result was not sensitive to the imputed value
used in the medical record review costing; all CIs
remained overlapping.
Event identification
The deﬁnition of a single event was not consistent
between the two sets of resource use, with some episodes
recorded as single events in medical record review data
appearing as multiple events in HES and vice versa.
Therefore, events in the data sets were not congruent;
minor differences in dates and lengths of stay were also
common. However, there was no ambiguity where men
had zero events recorded in one or the other data set.
Eleven men (3.8%) for whom events were recorded in
HES had all these events missing from medical record
review; similarly, 7 men (2.4%) with no events according
to HES had events identiﬁed in medical record review.
DISCUSSION
The end-of-life inpatient cost proﬁles derived using HES
and medical record review data were broadly similar.
Using HES data resulted in slightly lower costs overall
than using medical record review data. HES costs repre-
sented ∼92% of medical record review costs, although
there was no evidence of a true difference. This suggests
that it should be possible to use either of the two costing
methods in randomised controlled trials. It is unlikely
that the discrepancy in costs can be explained by events
not having been captured in HES. Eleven men had
events in HES but no events picked up by medical
record review; this is likely to have arisen as a result of
difﬁculties tracing events that may have occurred in hos-
pitals not approached during the medical record review
process. However, seven men had events identiﬁed in
medical record review and no events in HES, suggesting
that HES does not represent a completely accurate gold
standard.
Requesting data from ﬁnance departments proved
very difﬁcult, and was ultimately an unsuccessful
approach. This may have been linked to the volume of
information being requested, as the fastest turnaround
arose with the shortest questionnaire. In the absence of
a formal responsibility for trusts to supply the data,
responding to a request appeared to be low on a list of
priorities. The trusts all appeared to have different ways
of working, and for some it appeared that the ques-
tions asked were not meaningful. Although trusts were
asked to identify the different types of costs included in
their estimates, it was not always apparent that the data
supplied were directly comparable in terms of, for
example, inclusion of procedures undergone during a
hospital stay. The low response rate would have resulted
in a large degree of estimation for missing data, and
makes the ﬁnance department method unsuitable
for a CEA.
The HRG system is used to drive reimbursement and
create incentives for providers; as such, it does not
necessarily reﬂect the true opportunity costs of the
resources consumed. The nature of averages means that
hospitals will be overcompensated for some procedures
and underpaid for other, more costly, procedures. It is
Figure 1 End-of-life inpatient cost profiles for men who have
been diagnosed with prostate cancer; resource use was
identified through (A) medical record review and (B) Hospital
Episode Statistics (HES). National reference costs were used
to assign costs to the resource use.
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possible that the distribution of underpaid costly proce-
dures is concentrated in the ﬁnal year of life which
would accentuate any underpayment recorded.
Inevitably, however, a per diem costing method with a
cost applied for each day in hospital places considerable
emphasis on the length of stay, with the same costs
attributed to the ﬁrst and all subsequent days.27 This
may not reﬂect reality well, as it is more likely that there
are variable living and medical costs throughout an
episode with higher costs at the start of an episode.
A study based on Scottish data has looked at ﬁve differ-
ent methods of costing hospital inpatient stays, compar-
ing two DRG-based costing methods and three methods
incorporating a per diem approach.27 The authors found
substantial differences in overall costs depending on the
costing method employed with higher costs observed
when using a per diem approach, and recommended
using an HRG-based costing method. However, the study
was restricted to acute episodes, and did not use the
English HES data set. Microcosting approaches attempt
to identify and include all relevant costs in some detail; in
preliminary work, Dakin et al28 found that using HRG
data resulted in lower costs than microcosting in the
context of a trial studying age-related macular degener-
ation. A comparison of a DRG-based costing system with
microcosting in Ireland concluded that for disease areas
with high-cost treatments, DRG estimates do not yield
reliable results and microcosting should be considered.29
Our results add to this body of literature and suggest that
HRG-based costing methods are appropriate in some
instances.
The opportunity to reduce the cost of research
through the use of HES appears to be a compelling
argument in favour of adopting this approach for
studies that require data extraction on large numbers
over a wide geographical area. Medical record review is
currently estimated by the CAP team to take 4–6 h per
review, and can take as long as 28 h. It would be unreal-
istic to undertake this very time-consuming process for a
large number of participants. Medical record review also
has the potential to overlook events that occur at hospi-
tals outside those visited by researchers. However, there
are some limitations associated with using HES data for
trial purposes. Coverage is restricted to England; there-
fore, studies with participants in other parts of the UK
will need to employ further methods to supplement the
HES data. Also, HRGs do not have the cost discrimin-
ation required to differentiate between, for example,
two similar surgical procedures; in this instance, a micro-
costing approach based on asking ﬁnance departments
for costs would still be necessary. For trials with long-
term follow-up, there are also speciﬁc problems relating
to changes in administrative methods over the years; for
example, high-cost items were included in base HRGs in
V.3.5, but were unbundled and assigned their own codes
in HRG V.4.0.30
The study has strengths, but also some limitations.
The strengths included the fact that we analysed the
data retrospectively, so it was possible to deﬁne the ﬁnal
year of life accurately. Research assistants received twice
yearly training and review of their performance, so we
are conﬁdent that the data collection process in medical
record review was meticulous and comprehensive.
However, conclusions that can be reliably drawn from
this study are constrained by some limitations. Although
there is no reason to believe that any biases exist, the
sample was not selected completely at random. There is
a lack of clarity over the deﬁnition of a day case, with
some trusts classifying the same activity as an outpatient
event. This may have led to day cases being inaccurately
identiﬁed either in HES or medical record review22; day
case events were excluded from the study, but the confu-
sion may have led to some attribution errors. The men
included in this study were slightly more deprived on
average (IMD score=25.0) than the general population
of men in CAP (IMD score=22.9). Men who died rapidly
following diagnosis (within a year) were excluded; there-
fore, the study population is not a general one. Mean
imputation was used for missing costs in the medical
record review data, reducing the variance; however, this
does not affect the conclusions of the study. The ﬁnd-
ings in this study relate to men diagnosed with prostate
cancer, and it is uncertain whether these ﬁndings are
generalisable to other cancers or conditions. We do not
know whether the inpatient costs in the ﬁnal year of life
vary according to whether the man died of prostate
cancer or of another cause. For men dying of prostate
cancer, the cost of inpatient care in the ﬁnal year of life
has been estimated at ∼£7500,31 slightly lower than our
estimate for all men; we intend to explore this issue
using our data in the future when the sample size is
larger to allow precise estimation of stratiﬁed costs.
The purpose of this study was to investigate different
costing methods that could be employed in clinical
trials, and to validate the use of the HES inpatient data
set in particular; the costs derived should not, therefore,
be interpreted as end-of-life costs. The study was
restricted to inpatient resource use;18 however, informal
caregiving,32 chemotherapy33 and hospice care34 may
also be substantial in the end-of-life period. Derivation
of an overall cost of end-of-life prostate cancer care is
planned for future work.
CONCLUSIONS
Using HRGs from HES data coupled with NHS refer-
ence costs did not result in signiﬁcantly different
derived costs when compared with medical record
review costing methods. This suggests that it should be
acceptable to use routinely collected HES data in eco-
nomic evaluations conducted alongside randomised con-
trolled trials, although replication in alternative contexts
would be valuable. Neither HES nor medical record
review represent gold standards of resource-use data col-
lection, with some inpatient events missed from both
data sets.
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If data from medical record review are to be used,
applying national reference costs is the preferred costing
method as it is considerably less time consuming than
contacting ﬁnance departments, and results in a substan-
tially more complete data set. Researchers intending to
use data from ﬁnance departments should make contact
well in advance of requiring the data and anticipate a
low response rate.
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